These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32910065)

  • 1. Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents.
    Telwatte S; Kim P; Chen TH; Milush JM; Somsouk M; Deeks SG; Hunt PW; Wong JK; Yukl SA
    AIDS; 2020 Nov; 34(14):2013-2024. PubMed ID: 32910065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency.
    Telwatte S; Lee S; Somsouk M; Hatano H; Baker C; Kaiser P; Kim P; Chen TH; Milush J; Hunt PW; Deeks SG; Wong JK; Yukl SA
    PLoS Pathog; 2018 Nov; 14(11):e1007357. PubMed ID: 30440043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay.
    Yucha RW; Hobbs KS; Hanhauser E; Hogan LE; Nieves W; Ozen MO; Inci F; York V; Gibson EA; Thanh C; Shafiee H; El Assal R; Kiselinova M; Robles YP; Bae H; Leadabrand KS; Wang S; Deeks SG; Kuritzkes DR; Demirci U; Henrich TJ
    EBioMedicine; 2017 Jun; 20():217-229. PubMed ID: 28529033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
    Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
    PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART-treated women.
    Moron-Lopez S; Xie G; Kim P; Siegel DA; Lee S; Wong JK; Price JC; Elnachef N; Greenblatt RM; Tien PC; Roan NR; Yukl SA
    J Int AIDS Soc; 2021 Jul; 24(7):e25738. PubMed ID: 34235864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency.
    Zerbato JM; Khoury G; Zhao W; Gartner MJ; Pascoe RD; Rhodes A; Dantanarayana A; Gooey M; Anderson J; Bacchetti P; Deeks SG; McMahon J; Roche M; Rasmussen TA; Purcell DF; Lewin SR
    EBioMedicine; 2021 Mar; 65():103241. PubMed ID: 33647768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.
    Kula A; Delacourt N; Bouchat S; Darcis G; Avettand-Fenoel V; Verdikt R; Corazza F; Necsoi C; Vanhulle C; Bendoumou M; Burny A; De Wit S; Rouzioux C; Rohr O; Van Lint C
    J Acquir Immune Defic Syndr; 2019 Apr; 80(5):605-613. PubMed ID: 30768485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
    Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity in HIV and cellular transcription profiles in cell line models of latent and productive infection: implications for HIV latency.
    Telwatte S; Morón-López S; Aran D; Kim P; Hsieh C; Joshi S; Montano M; Greene WC; Butte AJ; Wong JK; Yukl SA
    Retrovirology; 2019 Nov; 16(1):32. PubMed ID: 31711503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
    Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
    mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4
    Kulpa DA; Talla A; Brehm JH; Ribeiro SP; Yuan S; Bebin-Blackwell AG; Miller M; Barnard R; Deeks SG; Hazuda D; Chomont N; Sékaly RP
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103
    Yukl SA; Khan S; Chen TH; Trapecar M; Wu F; Xie G; Telwatte S; Fulop D; Pico AR; Laird GM; Ritter KD; Jones NG; Lu CM; Siliciano RF; Roan NR; Milush JM; Somsouk M; Deeks SG; Hunt PW; Sanjabi S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo.
    Timmons A; Fray E; Kumar M; Wu F; Dai W; Bullen CK; Kim P; Hetzel C; Yang C; Beg S; Lai J; Pomerantz JL; Yukl SA; Siliciano JD; Siliciano RF
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15763-15771. PubMed ID: 32571938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA.
    Taylor JP; Armitage LH; Aldridge DL; Cash MN; Wallet MA
    Biol Open; 2020 Dec; 9(12):. PubMed ID: 33234703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection.
    Mann JFS; Pankrac J; Klein K; McKay PF; King DFL; Gibson R; Wijewardhana CN; Pawa R; Meyerowitz J; Gao Y; Canaday DH; Avino M; Poon AFY; Foster C; Fidler S; Shattock RJ; Arts EJ
    EBioMedicine; 2020 Sep; 59():102853. PubMed ID: 32654992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.
    Procopio FA; Fromentin R; Kulpa DA; Brehm JH; Bebin AG; Strain MC; Richman DD; O'Doherty U; Palmer S; Hecht FM; Hoh R; Barnard RJ; Miller MD; Hazuda DJ; Deeks SG; Sékaly RP; Chomont N
    EBioMedicine; 2015 Aug; 2(8):874-83. PubMed ID: 26425694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.